On March 17, 2026, Indivior Pharmaceuticals, Inc. announced the issuance of $500 million principal amount of its 0.625% Convertible Senior Notes due 2031. The notes were issued under an indenture with U.S. Bank Trust Company, National Association, serving as trustee. The notes will accrue interest at a rate of 0.625% per annum, payable semi-annually, starting September 15, 2026, and will mature on March 15, 2031. The initial conversion rate is set at 24.0033 shares of common stock per $1,000 principal amount, representing a conversion price of approximately $41.66 per share, which is a 35% premium over the last reported sale price of the common stock prior to the issuance. The company has granted initial purchasers an option to purchase an additional $50 million principal amount of notes within 30 days of the offering. The proceeds from this offering will be utilized to prepay all outstanding principal and interest under a previous Note Purchase Agreement, effectively terminating that agreement. This strategic move is expected to enhance the company's liquidity position and reduce its debt obligations, although it may lead to some dilution for existing shareholders due to the conversion feature of the notes.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.